Skip to main content

17-07-2020 | Rheumatology | News | Article


FDA approves adalimumab-fkjp

Claire Barnard

medwireNews: The US FDA has approved another adalimumab biosimilar – adalimumab-fkjp – for the treatment of various rheumatic diseases.

Similar to the reference product, adalimumab-fkjp is approved for the treatment of rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, and ankylosing spondylitis, as well as plaque psoriasis and inflammatory bowel disease.

Adalimumab-fkjp is the sixth adalimumab biosimilar to be approved in the USA, with adalimumab-atto, -adbm, -adaz, -bwwd, and -afzb approved between 2016 and 2019.

medwireNews is an independent medical news service provided by Springer Healthcare. © 2020 Springer Healthcare part of the Springer Nature Group

Related content

See the research in context now

with trial summaries, expert opinion and congress coverage

Image Credits